The estimated Net Worth of Patrick K. Lucy is at least $482 Tausend dollars as of 2 January 2024. Patrick Lucy owns over 27,174 units of Dyadic International stock worth over $33,968 and over the last 10 years Patrick sold DYAI stock worth over $447,565.
Patrick has made over 17 trades of the Dyadic International stock since 2015, according to the Form 4 filled with the SEC. Most recently Patrick exercised 27,174 units of DYAI stock worth $33,968 on 2 January 2024.
The largest trade Patrick's ever made was exercising 27,174 units of Dyadic International stock on 2 January 2024 worth over $33,968. On average, Patrick trades about 2,670 units every 108 days since 2014. As of 2 January 2024 Patrick still owns at least 27,174 units of Dyadic International stock.
You can see the complete history of Patrick Lucy stock trades at the bottom of the page.
Patrick's mailing address filed with the SEC is C/O DYADIC INTERNATIONAL INC, 1044 NORTH U.S. HIGHWAY ONE, SUITE 201, JUPITER, FL, 33477-5094.
Over the last 5 years, insiders at Dyadic International have traded over $118,246,658,250 worth of Dyadic International stock and bought 27,000 units worth $100,230 . The most active insiders traders include Mark A Emalfarb, Ronen Tchelet und Seth Herbst. On average, Dyadic International executives and independent directors trade stock every 73 days with the average trade being worth of $54,365. The most recent stock trade was executed by Barry Buckland on 11 June 2024, trading 11,793 units of DYAI stock currently worth $18,751.
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-S-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and research collaborations with Jiangsu Hengrui Medicine, Serum Institute of India Pvt., Ltd., and WuXi Biologics. It also has a collaboration with TurtleTree Scientific Pte. Ltd. to develop various recombinant protein growth factors; and a partnership agreement with Medytox, Inc. and Syngene International Limited to develop COVID-19 vaccines and/or boosters. The company was founded in 1979 and is headquartered in Jupiter, Florida.
Dyadic International executives and other stock owners filed with the SEC include: